It is worth noting that the methylation events of the promoter in IGF2BP1 at least involve the selected process because high promoter methylation of IGF2BP1 was demonstrated to block β-catenin binding to the IGF2BP promoter, leading to inactivation of the gene and enhancing proliferation and migration of metastatic breast cancer cells (Fig. 1d) [54, 103]. Here, IGF2BP1 is linked to breast cancer.